^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Clin Lymphoma Myeloma Leuk
    Title:

    Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma

    Published date:
    07/02/2021
    Excerpt:
    Patients aged ≥18 years with relapsed CD20-positive indolent B-cell lymphoma received copanlisib (45 mg, increasing to 60 mg if no dose-limiting toxicities) weekly on an intermittent schedule with R-B or R-CHOP...Among evaluable patients, objective response rates were 90% (5 complete, 4 partial) and 100% (3 complete, 7 partial) with copanlisib plus R-B and R-CHOP, respectively....Copanlisib is the first PI3K inhibitor to demonstrate safe, tolerable, and effective combinability with immunochemotherapy in patients with relapsed indolent B-cell lymphoma...
    Secondary therapy:
    bendamustine
    DOI:
    10.1016/j.clml.2021.06.021
    Trial ID:
    CHRONOS-4
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

    Excerpt:
    ...Patients must be CD20 positive....
    Trial ID:
    FIL_Copa-RB
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

    Excerpt:
    ...- Confirmed CD20 positive MALT Lymphoma de novo or relapsed following or being...
    Trial ID:
    NCT03474744